Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nightstar Therapeutics PLC

Division of Biogen Inc.
www.nightstarx.co.uk

Latest From Nightstar Therapeutics PLC

Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness

Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.

Financing Deals

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

Beyond The Watershed: Gene Therapy Investment And Promise

Janet Lambert, CEO of the Alliance of Regenerative Medicines recently spoke to In Vivo about the tremendous levels of investment the cell and gene therapy industries are attracting, as well as reasons why Europe excels at incubating advanced product development.

Gene Therapy Regenerative Medicine

Roche Confident Spark Therapeutics Acquisition Will Complete In First Half

US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but it is still on track for completion in the first half of 2019.

 

Deals Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Nightstar Therapeutics Ltd.
  • NightstaRx Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Biogen Inc.
  • Senior Management
  • David Fellows, CEO
    Senthil Sundaram, CFO
    Gregory Robinson, PhD, CSO
    Tuyen Ong, MD, Chief Dev. Officer
  • Contact Info
  • Nightstar Therapeutics PLC
    Phone: (0)20 7611 2077
    9-10 Midford Pl.
    London, W1T 5BJ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register